Sutro Biopharma STRO Other Noncash Income (Expense)
Other Noncash Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's other noncash income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's other noncash income (expense)?
- Sutro Biopharma (STRO) reported other noncash income (expense) of -$109K in Q1 2026.
- How has Sutro Biopharma's other noncash income (expense) changed year-over-year?
- Sutro Biopharma's other noncash income (expense) increased by 35.1% year-over-year, from -$168K to -$109K.
- What is the long-term trend for Sutro Biopharma's other noncash income (expense)?
- Over 3 years (2021 to 2025), Sutro Biopharma's other noncash income (expense) has grown at a -22.6% compound annual growth rate (CAGR), from -$1.23M to -$571K.
- What does other noncash income (expense) mean?
- This captures miscellaneous non-cash adjustments to net income that do not fit into standard categories like depreciation or stock-based compensation. It includes items such as changes in fair value of certain liabilities or non-cash impairment charges.